Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jourdan

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
Blood|April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureJérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
JAMA Network Open|April 20, 2019
Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell LymphomaSylvain Lamure, Camille Carles, Quam Aquereburu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experienceEric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
Blood|April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureJérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
JAMA Network Open|April 20, 2019
Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell LymphomaSylvain Lamure, Camille Carles, Quam Aquereburu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experienceEric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Pageof 9